StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Investment analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a note issued to investors on Monday. The firm set a "sell" rating on the stock.

Separately, Piper Sandler reissued an "overweight" rating and set a $4.50 price objective on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Price Performance

Shares of InspireMD stock traded up $0.06 during trading hours on Monday, hitting $2.59. 18,431 shares of the company's stock traded hands, compared to its average volume of 25,024. The stock has a market capitalization of $67.55 million, a price-to-earnings ratio of -3.37 and a beta of 0.93. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42. The company has a fifty day simple moving average of $2.58 and a 200-day simple moving average of $2.60.

InspireMD (NYSE:NSPR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter last year, the company posted ($0.15) earnings per share. On average, analysts forecast that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

Several institutional investors have recently added to or reduced their stakes in the business. Rosalind Advisors Inc. raised its position in shares of InspireMD by 266.4% in the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company's stock valued at $6,272,000 after purchasing an additional 1,827,579 shares during the period. Affiance Financial LLC bought a new stake in InspireMD during the 3rd quarter valued at $492,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD during the third quarter worth $279,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.